CNS Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 16, 2026, disclosing a net loss of $2.499 million for the third quarter and cash and cash equivalents of $17.212 million at quarter end.

Key Highlights

  • Net loss of $2.499 million for the three months ended September 30, 2026, compared to a net loss of $3.218 million in the same period of 2025, according to the filing.
  • Cash and cash equivalents of $17.212 million at September 30, 2026, up from $7.201 million at December 31, 2025, the company disclosed.
  • Total operating expenses of $2.665 million in Q3 2026, comprised of $890 thousand in research and development and $1.775 million in general and administrative expenses.
  • Shares outstanding of 1,475,699 as of November 15, 2026, up from 632,516 at December 31, 2025, the filing stated.
  • Accumulated deficit of $110.299 million as of September 30, 2026, compared to $100.275 million at December 31, 2025.
  • Proceeds from sale of common stock and pre-funded warrants, net, totaled $21.208 million for the nine months ended September 30, 2026, per the cash flow statement.

CNS Pharmaceuticals Reports Q3 2026 Financial Results and Balance Sheet Position

According to the filing, CNS Pharmaceuticals (NASDAQ:CNSP) reported a net loss of $2.499 million for the three months ended September 30, 2026, an improvement from the $3.218 million net loss recorded in the comparable prior-year quarter. For the nine months ended September 30, 2026, the company disclosed a net loss of $10.024 million, compared to $9.895 million for the same period in 2025. Loss per share on a basic and diluted basis was $(0.24) for Q3 2026, versus $(5.76) in Q3 2025, reflecting a significantly higher weighted average share count of 10,612,518 versus 558,868.

The company reported total operating expenses of $10.341 million for the nine months ended September 30, 2026, which included $5.636 million in research and development costs and $4.705 million in general and administrative expenses. The filing noted interest income of $330 thousand for the nine-month period, contributing to total other income of $317 thousand after interest expense of $13 thousand.

On the balance sheet, total assets stood at $18.064 million as of September 30, 2026, up from $8.623 million at December 31, 2025, the company disclosed. Total liabilities declined to $2.359 million from $4.100 million over the same period, while total stockholders' equity increased to $15.705 million from $4.523 million. The improvement in cash was driven primarily by financing activities, which provided net cash of $20.982 million during the nine months, including net proceeds from the sale of common stock and pre-funded warrants. Net cash used in operating activities was $10.961 million for the nine-month period. The filing also noted that in the first quarter of 2026, the company announced the formation of a new executive team.

What Was Disclosed

CNS Pharmaceuticals filed its unaudited quarterly financial statements for the period ended September 30, 2026, reporting a third-quarter net loss of $2.499 million, cash of $17.212 million, and an accumulated deficit of $110.299 million, with 1,475,699 shares outstanding as of November 15, 2026.